ReviewNature reviews. Clinical oncology2012
Patient-derived tumour xenografts as models for oncology drug development.
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02363647 (Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer), which is not on this map. Cited by 763 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer
Who cites it
763 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,286 citations in OpenAlex.
- Application and prospect of organoid technology in breast cancer.Frontiers in immunology · 2024Pooled it
- Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Orthotopic Implants in Mice.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Precision gene editing in infant neuroblastoma: a review of nanoparticle: enabled CRISPR/Cas9 therapies.Molecular biology reports · 2026Review
- Linking preclinical models with functional imaging and artificial intelligence to decode tumor angiogenesis.Pharmacological reports : PR · 2026Review
- Improved Method for Obtaining Patient-Derived Glioblastoma Organoid and Primary Cells: A Generic and Simplified Approach for Intracranial Tumor With Minimized Input.CNS neuroscience & therapeutics · 2026Article
- Modeling Tenascin-C-rich metastatic tumor niches in engineered hydrogel biomaterials.Acta biomaterialia · 2026Article
- The molecular similarity landscape of preclinical cancer models to patient tumors.JCI insight · 2026Article
- SACF and GILA for in vitro transformation assessment of CRISPR/Cas9-edited cell therapy candidates: a multi-site study.Gene therapy · 2026Article
- Bladder cancer organoids in precision medicine: bridging basic science, clinical therapeutics and drug development.Cancer cell international · 2026Review
- Real-time cell viability monitoring for high-throughput drug screening using tumor xenograft-derived cells.Cell reports methods · 2026Article
- [Standardized Construction of Lung Cancer Organoids and Their Application Progress in the Precise Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Patient-derived three-dimensional lung tumor models to evaluate response to therapy.NPJ precision oncology · 2026Article
- Identification of ANC-3 as a Novel Therapeutic Candidate for Anaplastic Thyroid Cancer Through Drug Screening and Multi-Platform Validation.International journal of molecular sciences · 2026Article
- From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models.Advanced healthcare materials · 2026Review
- Article
- Article
- Targeting cancer-associated fibroblast-activated HGF/c-MET pathway inhibits extrahepatic cholangiocarcinoma progression and restores gemcitabine therapeutic sensitivity.Acta pharmaceutica Sinica. B · 2026Article
- Review
- A novel hairless highly immunodeficient mice model optimized for in vivo imaging.Laboratory animal research · 2026Article
703 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Progress in oncology drug development has been hampered by a lack of preclinical models that reliably predict clinical activity of novel compounds in cancer patients. In an effort to address these shortcomings, there has been a recent increase in the use of patient-derived tumour xenografts (PDTX) engrafted into immune-compromised rodents such as athymic nude or NOD/SCID mice for preclinical modelling. Numerous tumour-specific PDTX models have been established and, importantly, they are biologically stable when passaged in mice in terms of global gene-expression patterns, mutational status, metastatic potential, drug responsiveness and tumour architecture. These characteristics might provide significant improvements over standard cell-line xenograft models. This Review will discuss specific PDTX disease examples illustrating an overview of the opportunities and limitations of these models in cancer drug development, and describe concepts regarding predictive biomarker development and future applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.